Home - Products - Others - Other Targets - Pelargonidin-3,5-O-diglucoside chloride

Pelargonidin-3,5-O-diglucoside chloride

CAS No. 17334-58-6

Pelargonidin-3,5-O-diglucoside chloride ( )

Catalog No. M31224 CAS No. 17334-58-6

Pelargonidin-3,5-O-diglucoside chloride has antioxidant activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 639 In Stock
50MG Get Quote In Stock
100MG Get Quote In Stock

Biological Information

  • Product Name
    Pelargonidin-3,5-O-diglucoside chloride
  • Note
    Research use only, not for human use.
  • Brief Description
    Pelargonidin-3,5-O-diglucoside chloride has antioxidant activity.
  • Description
    Pelargonidin-3,5-O-diglucoside chloride has antioxidant activity.
  • Synonyms
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    17334-58-6
  • Formula Weight
    631
  • Molecular Formula
    C27H31O15Cl
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • RGD Trifluoroacetate

    RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; RGD Trifluoroacetate binds to integrins.RGD Trifluoroacetate is the most effective and most often employed peptide sequence for stimulated cell adhesion on synthetic surfaces. There are 24 integrins binding to ECM molecules in a RGD dependent manner: α3β1, α5β1, α8β1, αIIbβ3, αvβ1, αvβ3, αvβ5, αvβ6, αvβ8, and to some extent α2β1 and α4β1.

  • DHODH-IN-4

    DHODH-IN-4 is a human and Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) inhibitor.

  • Moracin P

    Moracin P exhibits potent in vitro inhibitory activity against hypoxia-inducible factor (HIF-1), which is a key mediator during adaptation of cancer cells to tumour hypoxia.